Credit Suisse’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $19.3M | Buy |
1,936,970
+234,914
| +14% | +$2.34M | 0.02% | 640 |
|
|
2023
Q4 | $16.8M | Buy |
1,702,056
+15,170
| +0.9% | +$150K | 0.02% | 707 |
|
|
2023
Q3 | $12.9M | Sell |
1,686,886
-13,005
| -0.8% | -$99.5K | 0.01% | 795 |
|
|
2023
Q2 | $12.7M | Buy |
1,699,891
+117,518
| +7% | +$878K | 0.01% | 812 |
|
|
2023
Q1 | $10.6M | Buy |
1,582,373
+6,783
| +0.4% | +$45.2K | 0.01% | 899 |
|
|
2022
Q4 | $12.1M | Buy |
1,575,590
+10,235
| +0.7% | +$78.9K | 0.01% | 833 |
|
|
2022
Q3 | $16.7M | Buy |
1,565,355
+302
| +0% | +$3.21K | 0.02% | 714 |
|
|
2022
Q2 | $12.7M | Buy |
1,565,053
+451
| +0% | +$3.67K | 0.01% | 840 |
|
|
2022
Q1 | $11.2M | Buy |
1,564,602
+4,984
| +0.3% | +$35.7K | 0.01% | 991 |
|
|
2021
Q4 | $26.7M | Buy |
1,559,618
+109,022
| +8% | +$1.87M | 0.01% | 694 |
|
|
2021
Q3 | $33.4M | Buy |
1,450,596
+1,011
| +0.1% | +$23.3K | 0.02% | 608 |
|
|
2021
Q2 | $52.9M | Buy |
+1,449,585
| New | +$52.9M | 0.03% | 475 |
|